Not coincidentally, EZH2 inhibitors were also able to promote STING pathway-mediated T-cell infiltration and antitumor effects (Morel et al., 2021; Xu et al., 2021), suggesting that these two inhibitors may play synergistic roles in modulating the tumor immune microenvironment. Here, EZH2 is linked to neoplasm.